The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge
暂无分享,去创建一个
G. Ruiz-Argüelles | D. Gómez-Almaguer | J. Jaime-Pérez | G. Ruiz-Delgado | I. Murrieta-Alvarez | A. León-Peña | Y. Cantero-Fortiz | J. M. Priesca-Marín | E. Gonzalez-Lopez | Andrés Gómez-de-León | J. Olivares-Gazca
[1] Carmina Alejandra Córdova-Ramírez,et al. Early Response Predicts Long-Term Improvement or Stabilization of Persons with Multiple Sclerosis Treated with Hematopoietic Stem Cell Transplantation , 2020 .
[2] G. Ruiz-Argüelles. Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting. , 2020, The Lancet Haematology.
[3] D. Cilloni,et al. Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients , 2020, Neurology and Therapy.
[4] D. Gómez-Almaguer,et al. Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant. , 2020, Cytotherapy.
[5] R. Gale,et al. Mélange intéressante: COVID-19, autologous transplants and multiple sclerosis , 2020, Hematology.
[6] G. Ruiz-Argüelles,et al. Respiratory impairment in persons with multiple sclerosis: A cross-sectional study , 2019 .
[7] G. Ruiz-Argüelles,et al. Self‐reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real‐world data from a single center , 2019, Clinical and experimental immunology.
[8] D. Fedorenko,et al. Long-term outcomes of nonmyeloablative autologous hematopoietic stem cell transplantation in multiple sclerosis , 2019, Journal of the Neurological Sciences.
[9] R. Gale,et al. Determine safety of outpatient chemotherapy and autotransplants using refrigerated, non‐frozen grafts in persons with multiple sclerosis , 2019, Clinical transplantation.
[10] Jeffrey A. Cohen,et al. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] B. Sharrack,et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial , 2019, JAMA.
[12] G. Ruiz-Argüelles,et al. Metabolomic profile of insulin resistance in patients with multiple sclerosis is associated to the severity of the disease. , 2018, Multiple sclerosis and related disorders.
[13] G. Ruiz-Argüelles,et al. Glomerular Filtration Rate in Patients with Multiple Sclerosis Undergoing Stem Cell Transplantation and Treated with Cyclophosphamide , 2018, Laboratory medicine.
[14] R. Gale,et al. Autotransplantations Without Cryopreservation , 2018, Journal of global oncology.
[15] J. Szer,et al. Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs? , 2017, Biology of Blood and Marrow Transplantation.
[16] G. Ruiz-Argüelles,et al. Hematopoietic stem cell transplants for persons with multiple sclerosis: Is this the best therapeutic option? , 2017 .
[17] M. Sormani,et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis , 2017, Nature Reviews Neurology.
[18] H. Atkins,et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis , 2017, JAMA neurology.
[19] D. Arnold,et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS , 2017, Neurology.
[20] G. Ruiz-Argüelles,et al. A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells , 2016, Acta Haematologica.
[21] G. Ruiz-Argüelles,et al. Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation. , 2016, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
[22] J. Johansson,et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[23] Pedagógia,et al. Cross Sectional Study , 2019 .
[24] B. Xu,et al. Treatment of mild–moderate calcified coronary lesions with sirolimus-eluting stent: real world data from a single center , 2010, Coronary artery disease.
[25] P. Madden. The Swedish experience. , 1988, The Health service journal.
[26] J. Gottdiener,et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. , 1981, Archives of internal medicine.